Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 1.00 |
| ▸ | JAK3 | P52333 | 5/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.74 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 13/20 | 0.70 |
| ▸ | MUSK | O15146 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490059 | 1.00 | JAK2 (1.00) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2490060 | 1.00 | JAK2 (1.00) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2489844 | 0.90 | JAK3 (0.82) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2488126 | 0.90 | JAK3 (0.82) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2485809 | 0.90 | JAK3 (0.82) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2485537 | 0.87 | JAK3 (0.77) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2485539 | 0.87 | JAK3 (0.77) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL5027420 | 0.87 | JAK2 (0.76) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL4883698 | 0.86 | JAK2 (0.76) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2487088 | 0.86 | JAK3 (0.76) | JAK2JAK3LIMK1LIMK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835465-B2 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2014-09-16 | — | — | US | disclosed |
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090358-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K2 | JAK2 226/4885JAK3 263/4885LIMK1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.